Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q1 2020 · 10-Q
Revenue$1.41M$1.41M+11.4% vs Q1 2019 Net Income-$15.59M-$15.59MN/M vs Q1 2019 EPS Diluted-$0.37-$0.37N/M vs Q1 2019 Operating Income-$15,506,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
Free Cash Flowderived-$6,929,000N/M Margins · derivedOperating margin-1102.1%+1039.7 pt vs Q1 2019
Net margin-1107.7%+1866.5 pt vs Q1 2019
ended Mar 31, 2020 · filed May 7, 2020 · 37 d after period end